Case report: Identification of Hepatitis B Virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumabImmunology Case Report Published on 2024-02-152024-09-05 Journal: Frontiers in immunology [Category] update2024, [키워드] Case report Hepatitis B virus inebilizumab Neuromyelitis optica spectrum disorders Ofatumumab [DOI] 10.3389/fimmu.2024.1351782 PMC 바로가기 [Article Type] Immunology Case Report
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumabCoronavirus Published on 2024-02-122024-09-05 Journal: Human vaccines & immunotherapeutics [Category] update2024, [키워드] COVID19 vaccination Neutralizing antibodies Ofatumumab relapsing multiple sclerosis T-cell responses [DOI] 10.1080/21645515.2024.2316422 PMC 바로가기 [Article Type] Coronavirus
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccinationArticle Published on 2022-08-312022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] alteration anti-CD20 anti-CD20 therapy antibody applied approach B cell caused CD4 Cellular immune response cellular immunity characterized Complete decrease Delta disorder dosage Effect elicit Frequency healthy controls humoral humoral immune response immune Immune cell immune cells immune response Immunosuppression implication information investigated mean treatment duration Multiple multiple sclerosis neutralization capacity Ofatumumab ofatumumab. omicron pandemic Patient preserved Regulatory T cell SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 variant sclerosis subcutaneously subpopulation sustained T cell T cell response T helper Th1 titer treated treated patient Treatment Tregs vaccination was impaired wild type [DOI] 10.3389/fimmu.2022.980526 PMC 바로가기
Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depletersTixagevimab 및 Cilgavimab(Evusheld)는 b 세포 고갈자에 대한 다발성 경화증 환자에서 SARS-CoV-2에 대한 항체 수준을 높입니다.Article Published on 2022-07-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Affect All participant antibody Antibody Response Antibody testing baseline boost cilgavimab cohort study COVID-19 COVID-19 vaccine creating demonstrated evaluate Evusheld highest Immunity Injections mRNA vaccination Multiple multiple sclerosis Ocrelizumab Ofatumumab Patient patient population performed protective immune response provide receiving SARS-CoV-2 single-center the antibody response the vaccine therapy Tixagevimab treated USA vaccination were measured [DOI] 10.1016/j.msard.2022.103905 PMC 바로가기 [Article Type] Article
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 yearsOriginal Research Papers Published on 2022-03-012024-09-04 Journal: Multiple Sclerosis Journal [Category] 대상포진, [키워드] antibodies monoclonal multiple sclerosis Ofatumumab relapsing multiple sclerosis Safety [DOI] 10.1177/13524585221079731 PMC 바로가기 [Article Type] Original Research Papers
Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disordersarticle Published on 2022-02-022024-09-02 Journal: Frontiers in immunology [Category] 대상포진, [키워드] immune-mediated diseases multiple sclerosis obinutuzumab Ocrelizumab Ofatumumab systemic lupus erythematosus ublituximab veltzumab [DOI] 10.3389/fimmu.2021.788830 PMC 바로가기 [Article Type] article
Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab오파투무맙으로 치료받은 다발성 경화증 환자의 회복기 COVID-19 환자의 체액 및 세포 면역Article Published on 2022-01-152022-09-11 Journal: Journal of neuroimmunology [Category] 임상, 진단, [키워드] Administered all subject all subjects antibodies Antibody Response Antibody testing CD19 CD19+ Cell cellular immunity Clinical outcome convalescent COVID-19 COVID-19 infection COVID-19 symptoms COVID-19 vaccination COVID-19 vaccinations dose ELISPOT four subject humoral IgG antibodies IgG antibody IgM IgM and IgG Immunity interferon interferon-γ lymphocyte mediated immunity Mild Multiple multiple sclerosis not performed Ofatumumab PCR performed Quotient reactive SARS-CoV-2 secreting single center subject T cell T-cell T-cell immunity Testing treated U/mL was performed was used while [DOI] 10.1016/j.jneuroim.2021.577788 PMC 바로가기 [Article Type] Article
B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control studyB 세포 고갈자는 다발성 경화증 환자에서 SARS-CoV-2 백신에 대한 체액 반응을 약화: 사례 대조 연구Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, 치료기술, [키워드] 95% CI absolute levels addition adjusted age ANCOVA antibody Antibody Response Antibody testing antigens approved attenuate attenuation B-cell case-control study center Comprehensive continuous variable covariate covariates COVID-19 COVID-19 infection depleting determine disease Disease modifying therapies dose enrolled FDA Final group humoral Humoral response Johnson & Johnson Johnson & Johnson Labcorp levels of antibody logistic regression models lymphocyte Lymphocyte count Moderna multiple sclerosis not differ Ocrelizumab Ofatumumab outcome p-values P-values <0.05 Patient patients treated Pfizer-BioNTech Quantitative raised recruited Research SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines semi-quantitative Sex shown sphingosine Spike protein tested the antibody response the SARS-CoV-2 the vaccine Therapies therapy Treatment Vaccine was tested [DOI] 10.1016/j.msard.2021.103413 PMC 바로가기 [Article Type] Article
Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseasesArticle Published on 2021-07-012023-06-01 Journal: Multiple sclerosis and related disorders [Category] 두창, 수두, 홍역, [키워드] Immunoglobulin G immunoglobulin M Infection multiple sclerosis Ocrelizumab Ofatumumab rituximab [DOI] 10.1016/j.msard.2021.102988
Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatmentCorrespondence Published on 2021-02-212024-09-04 Journal: Multiple sclerosis and related disorders [Category] 대상포진, [키워드] herpes zoster multiple sclerosis Ocrelizumab Ofatumumab rituximab Vaccines [DOI] 10.1016/j.msard.2021.102851 PMC 바로가기 [Article Type] Correspondence